Abstracts tagged "Treg cells"

Abstract Number: 0989 • ACR Convergence 2022
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Nandita Sarkar¹, Xuguang Hu¹, Nadia Tchao¹, Richard Furie², Alan Kivitz³, Stanley B Cohen⁴ and Kevin Gorski⁵, ¹Amgen Inc., South San Francisco, CA, ²Northwell Health, Great Neck, NY, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Regulatory T cells (Treg) are critical for maintaining self-tolerance and preventing autoimmunity, and IL-2 is essential for their development, survival and suppressive function. Defects…
Abstract Number: 1399 • ACR Convergence 2022
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Gregory McDermott¹, Jing Cui¹, Rachel Knevel², Kumar Dahal¹, Dana Weisenfeld¹, Priyam Das³, Elizabeth Karlson¹, Su-Chun Cheng⁴, Soumya Raychaudhuri¹, Tianxi Cai⁴ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Leiden University Medical Center, Leiden, Netherlands, ³Harvard Medical School, Boston, MA, ⁴Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1740 • ACR Convergence 2022
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
Tessnime Abaab¹, Lyna Mebrek¹, Marie-Christophe Boissier², Luca Semerano³, Jerome Biton¹ and Natacha Bessis¹, ¹INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France, ²INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ³Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are inflammatory autoimmune diseases associated with impaired regulatory T cell (Tregs) function. Tregs identity varies according to their…
Abstract Number: 1746 • ACR Convergence 2022
Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
María-Eugenia Miranda-Carús¹, Alejandro Villalba¹, Laura Nuño¹, Marta Benito-Miguel², Irene Monjo¹, Marta Novella-Navarro¹, Diana Peiteado¹, Sara Garcia-Carazo¹ and Alejandro Balsa³, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Universidad Nebrija, Physiology, Madrid, Spain, ³Hospital La Paz Institute for Health Research, Madrid, Spain
Background/Purpose: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system. Stressed cells at inflammatory foci release adenine nucleotides to…
Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Renuka Nayak³, Anthony Jimenez Hernandez¹, Sydney Catron⁴, Zakwan Uddin⁴, Erin Reilly⁵, Andrew Patterson⁵, Peter Turnbaugh⁶, Jose Clemente² and Jose Scher⁷, ¹NYU School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴NYU Langone Health, New York, NY, ⁵Pennsylvania State University, College Park, PA, ⁶UCSF, San Francisco, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
Abstract Number: 2183 • ACR Convergence 2022
mTORC2 Contributes to Murine Systemic Autoimmunity
Xian Zhou¹, Haiyu Qi¹, Meilu Li¹, Yanfeng Li¹, Xingxing Zhu², Anne Davidson³ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 1254 • ACR Convergence 2021
The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
Anna Abou-Raya, Darwish ELHallous, Mohamed Ossama, Nahla Farahat, Mohamed Khaled and Suzan Abou-Raya, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic immune-mediated heterogenous disease characterized by a defect in the compartment of regulatory CD4+Foxp3+ T cells (Treg) which are…
Abstract Number: 1438 • ACR Convergence 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Renan Vergara¹, Alex Chen¹, Jerry Chen¹, Marianne Riley¹, Luis Blancas-Mejia¹, Christie Mortales¹, Tania Berrocal¹, Tanu Priya¹, Marsha Mason¹, Kevin Yu¹, Olga Sharapova¹, Jorgen Nelson¹, Alfredo Quijano-Rubio¹, Thomas Linsky¹, Ryan Swanson¹ and Daniel-Adriano Silva², ¹Neoleukin Therapeutics, Inc., Seattle, WA, ²Formerly of Neoleukin Therapeutics, Inc., Seattle, WA
Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
Abstract Number: 1512 • ACR Convergence 2021
Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy
Philip Titcombe, Milagros Silva Morales and Daniel Mueller, University of Minnesota, Minneapolis, MN
Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
Abstract Number: 1734 • ACR Convergence 2021
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Nadia Tchao¹, Hamid Amouzadeh², Nandita Sarkar¹, Vincent Chow², Xuguang Hu¹, Mark Kroenke², Hui Wang², Rong Zhang², Kevin Gorski¹, Richard Furie³, Alan Kivitz⁴ and Stanley Cohen⁵, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
Abstract Number: 1774 • ACR Convergence 2021
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Michelle Mulder¹, Xuehui He², Juul van den Reek², Paulo Urbano², Charlotte Kaffa², Xinhui Wang³, Bram van Cranenbroek², Esther van Rijssen², Frank van den Hoogen⁴, Irma Joosten², Wynand Alkema⁵, Elke de Jong², Ruben Smeets², Mark Wenink⁶ and Hans Koenen², ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboud University Medical Center, Nijmegen, Netherlands, ³University of Luxembourg, Belvaux, Luxembourg, ⁴Sint Maartenskliniek, Ubbergen, Netherlands, ⁵Hanze University of Applied Sciences, Groningen, Netherlands, ⁶Sint Maartenskliniek, Malden, Netherlands
Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…
Abstract Number: 0471 • ACR Convergence 2021
Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, Sarah Fitch, Jyoti Chauhan and Josep Bassaganya-Riera, Landos Biopharma, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 0547 • ACR Convergence 2021
Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells
Ross Penglase, Malini Visweswaran, John Zaunders, Laila Girgis, David Ma and John Moore, St Vincent's Hospital, Sydney, Australia
Background/Purpose: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is an effective treatment for severe systemic sclerosis (SSc). To date, mechanistic studies have indicated possible pro-regulatory and…
Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt¹, Kevin Wei², Siobhan Case³, Margaret Chang¹, Ezra Cohen¹, Fatma Dedeoglu¹, Melissa Hazen¹, Jonathan Hausmann⁴, Olha Halyabar⁵, Erin Janssen⁵, Pui Lee⁶, Jeffrey Lo¹, Mindy Lo¹, Esra Meidan⁷, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel⁵, Talal Chatila¹, Peter Nigrovic⁸ and Lauren Henderson⁹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵Children's Hospital/Boston Medical Center, Boston, MA, ⁶1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁷Boston Children's Hospital, Somerville, MA, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁹Boston Children's Hospital, Watertown, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].